RhEPO also has additional safety concerns such as increased risk of venous thromboembolism, stroke, myocardial infarction (MI), heart failure and death owing to the supraphysiological EPO levels leading to sudden and/or excessive haemoglobin (Hgb) levels (15–18). Here, EPO is linked to myocardial infarction.